Nanfang CNC

Chongqing Nanfang CNC Equipment Co., Ltd. (referred to as "Nanfang CNC" or "the Company", stock code: 873512) was founded in 2004 and converted into a joint-stock company in 2019. It is a technology-innovation-oriented enterprise specializing in the research and development, production, sales, and service of in vitro diagnostic (IVD) reagents and instruments. The Company is one of the earlier domestic enterprises engaged in the R&D, production, and sales of IVD products. The core values of Nanfang CNC are "people-oriented, technological innovation." It is a National High-tech Enterprise, a Chongqing Enterprise Technology Center, a Chongqing New-Type Research and Development Institution, a Chongqing Specialized, Refined, Distinctive, and Innovative SME, and a Chongqing SME Little Giant. The Company's products have received policy support and awards including project approval from the Technology Innovation Fund for Technology-based SMEs of the Ministry of Science and Technology of China, and designation as a demonstration product of the "Ten Hundred Thousand Project" for domestic innovative medical devices by the Ministry of Science and Technology of China. The Company has always focused on the field of thrombosis and hemostasis in vitro diagnostics within the field of hemodynamics, forming a core technology cluster covering instruments, reagents, and consumables, with outstanding independent R&D and technological innovation capabilities. The Company is a vice president unit of the Chongqing Medical Device Industry Association. Over the years, it has provided high-quality products and services to a large number of customers and accumulated rich customer resources. From the 47th China International Medical Equipment Fair in April 2002 to the 82nd now, the Company has continuously participated in the exhibitions without interruption, competing on the same stage with the strongest and most professional peers both domestically and internationally, demonstrating the advanced nature of its products, building brand trust, establishing high-quality customer resources and marketing channels for the Company's sustainable development, and building a good brand image, ensuring the steady increase of the Company's market share in in vitro diagnostics and sustainable profit development. It has been rated as a Grade A taxpaying enterprise for seven consecutive years.